Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment ...
The Deputy Secretary of State is trawling through social media to revoke papers from people who criticize the US, fueling a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback